Protect Patients and Innovation from ICER

As states continue to grapple with prescription drug costs, “cost-effectiveness” reviews are being considered as one method to determine treatment access and reimbursement decisions. Pioneer Institute explores the potential impacts that ICER and one-size-fits-all methods to healthcare value assessment could have for certain patient populations and medical innovation itself.

Get Updates on our Work to Protect Patients and Innovation!

Name
First Last
Email

Get Updates on our Work to Protect Patients and Innovation!

Name
First Last
Email

Read Our Research:

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

May 21, 2020/by Editorial Staff

New Report: Quality Adjusted Life Years (QALY) Methodology Discriminates Against Older Americans, Threatens to Deny Seniors Access to Life-Saving Care

April 2, 2020/by Editorial Staff

Recent Media Coverage:

Report: Rare Disease Patients Hurt by “One-Size-Fits-All” ICER Framework

June 26, 2019/by Editorial Staff

Putting a Price on Life: The Coming Fight Over Government Rationing of Medical Care

June 12, 2019/by Editorial Staff

Here’s why Sarah Palin’s ‘death panels’ are now being debated in Massachusetts

April 25, 2019/by Editorial Staff

Issue Brief: Problems With The Institute of Clinical and Economic Review (ICER) and the QALY Methodology

April 23, 2019/by Editorial Staff

Protect Patients and Innovation from ICER

Protect Patients and Innovation from ICER

Get Updates on our Work to Protect Patients and Innovation!

Get Updates on our Work to Protect Patients and Innovation!

Read Our Research:

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

New Report: Quality Adjusted Life Years (QALY) Methodology Discriminates Against Older Americans, Threatens to Deny Seniors Access to Life-Saving Care

Recent Media Coverage:

Report: Rare Disease Patients Hurt by “One-Size-Fits-All” ICER Framework

Putting a Price on Life: The Coming Fight Over Government Rationing of Medical Care

Here’s why Sarah Palin’s ‘death panels’ are now being debated in Massachusetts

Issue Brief: Problems With The Institute of Clinical and Economic Review (ICER) and the QALY Methodology

Commentary: Proposed Drug Price Caps Would Stall Advances in Health Care

HHS Secretary Alex Azar doesn’t want drug access to become an equation

The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews

Baker’s Orwellian drug pricing policy

Make a tax-deductible gift below to support our work to protect patients.